Article Details

Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli

Retrieved on: 2022-08-03 10:00:13

Tags for this article:

Click the tags to see associated articles and topics

Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli. View article details on hiswai:

Excerpt

The U.S. Food and Drug Administration ((FDA)) approved Coherus BioSciences' (CHRS) Cimerli, a biosimilar interchangeable of Roche's (RHHBY) ...

Article found on: seekingalpha.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up